Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Hypertension
Sponsored by: AstraZeneca
Official(s) and/or principal investigator(s):
R. E. Schmieder, MD, Principal Investigator, Affiliation: University hospital Erlangen-Nurnberg
Andrea Pahor, MD, Study Chair, Affiliation: MED Dep., AstraZeneca Germany
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12. 5 mg
candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions,
i. e. under routine medical care conditions, the subject compliance as well as the efficacy
and tolerability of candesartan or candesartan/HCT in subjects suffering from essential
Official title: Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period.
To assess under naturalistic conditions the subject's reason(s) for being compliant or non-compliant with the intake of the pre-scribed dose of candesartan or candesartan/HCT
To assess under naturalistic conditions the subject's reason(s) for withdrawal of the pre-scribed dose of candesartan or candesartan/HCT
To assess under naturalistic conditions whether physicians are using procedures to improve the subject's compliance regarding the intake of candesartan or candesartan/HCT and to get insight in the type and effects of these procedures
Minimum age: N/A.
Maximum age: N/A.
- essential hypertension
- under candesartan treatment
Locations and Contacts
Starting date: January 2007
Last updated: February 5, 2008